# A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

> **NCT07281976** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nanjing Leads Biolabs Co.,Ltd** · enrollment: 220 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** LBL-024 for Injection
- **DRUG:** albumin-bound Paclitaxel injection
- **DRUG:** Toripalimab Injection

## Key facts

- **NCT ID:** NCT07281976
- **Lead sponsor:** Nanjing Leads Biolabs Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281976, "A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07281976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*